EUVIMEDEUVIMED entdecken
Open Access

Prospective, Longitudinal Study of Cancer Predictors and Rates in a New York City Cohort of 598 Patients With Acromegaly

Pamela U Freda iD, Jeffrey N Bruce iD, Zhezhen Jin, Jane Kostadinov, Alexander G Khandji, Serge Cremers, Kalmon D Post

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgae469 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Pamela U Freda und 6 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Medicine, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA. Hauptthemen laut MEDLINE: Acromegaly, Insulin-Like Growth Factor I, Pituitary Neoplasms, Adenoma. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Columbia University, NCRR NIH HHS, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Long-term growth hormone/insulin-like growth factor-1 (GH/IGF-1) excess could increase the risk of cancer in acromegaly, but individual levels of these hormones do not relate to this risk.

Objective

We newly investigated longitudinally-measured IGF-1 levels as a potential predictor of cancer in a large New York City acromegaly cohort.

Methods

We conducted a prospective, longitudinal study of 598 acromegaly (309 men, 289 women) and 292 clinically nonfunctioning pituitary adenoma (CNFPA) (140 women, 152 men) patients from the same underlying population. GH and IGF-1 levels were measured longitudinally and outcomes were observed during long-term follow-up. Cumulative exposure to IGF-1 excess was tested as a predictor of cancer. We compared cancer prevalence in acromegaly and CNFPA cohorts and incidence in each to that expected from Surveillance, Epidemiology, and End Results (SEER) data.

Results

Cancer prevalence by last follow-up was 22.6% in acromegaly and 12.7% in CNFPAs (odds ratio [OR] = 1.99 [95% CI, 1.34-2.97]) (P = .0005). Overall standardized incidence ratio for cancer was 1.78 (1.51-1.81) in the acromegaly and 1.26 (0.89-1.70) in the CNFPA cohorts. Cumulative exposure to IGF-1 excess, OR = 1.278 (1.060-1.541) (P = .01), years from acromegaly diagnosis to cancer or last follow-up, OR = 1.03 (1.004-1.057) (P = .024), and age at follow up, OR = 1.064 (1.047-1.082) (P < .001), were predictors of cancer.

Conclusion

Cancer risk is increased in acromegaly, but not in CNFPA patients. Cumulative exposure to IGF-1 excess is a predictor of cancer in acromegaly. Our data suggest that cancer risk in acromegaly relates to the degree and duration of IGF-1 excess and that full appreciation of this risk requires long-term follow up.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcromegalyInsulin-Like Growth Factor IPituitary NeoplasmsAdenomaNeoplasmsHumansFemaleMaleMiddle AgedNew York CityLongitudinal StudiesAdultProspective StudiesAgedHuman Growth HormonePrevalenceIncidenceRisk FactorsCohort StudiesFollow-Up Studies

Stichwörter der Autor:innen

IGF-1acromegalycancerpituitary tumor

Substanzen

Insulin-Like Growth Factor IHuman Growth HormoneIGF1 protein, human

Autor:innen und Institutionen

  • Departments of Medicine, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA.
  • Neurosurgery, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA.
  • Biostatistics, Mailman School of Public Health, Columbia University, New York, NY 10032, USA.
  • Department of Neurosurgery, Mt. Sinai School of Medicine, New York, NY 10029, USA.
  • Radiology, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA.
  • Pathology and Cell Biology, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA.

ORCID-Profile: Pamela U Freda, Jeffrey N Bruce

Förderung

  • Columbia University
  • NCRR NIH HHS
  • NIDDK NIH HHS
  • CTSA
  • IPSEN, Inc
  • NIH HHS
  • NCATS NIH HHS
  • NINDS NIH HHS

Zitieren

APA

Freda, P. U., Bruce, J. N., Jin, Z., Kostadinov, J., Khandji, A. G., Cremers, S., & Post, K. D. (2025). Prospective, Longitudinal Study of Cancer Predictors and Rates in a New York City Cohort of 598 Patients With Acromegaly. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae469

Vancouver

Freda PU, Bruce JN, Jin Z, Kostadinov J, Khandji AG, Cremers S, et al. Prospective, Longitudinal Study of Cancer Predictors and Rates in a New York City Cohort of 598 Patients With Acromegaly. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae469

BibTeX
@article{Freda2025,
  author = {Freda, Pamela U and Bruce, Jeffrey N and Jin, Zhezhen and Kostadinov, Jane and Khandji, Alexander G and Cremers, Serge and Post, Kalmon D},
  title = {Prospective, Longitudinal Study of Cancer Predictors and Rates in a New York City Cohort of 598 Patients With Acromegaly},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgae469}
}
Kostenlos starten →